Delving into the Latest Updates on 18F-CNY-07 with Synapse

Overview

Basic Info

Drug Type

Diagnostic radiopharmaceuticals

Synonyms-

Target

RIPK1

Action

modulators

Mechanism

RIPK1 modulators(Receptor-interacting serine/threonine-protein kinase 1 modulators)

Therapeutic Areas

Nervous System Diseases

Active Indication

Central Nervous System Diseases

Inactive Indication-

Originator Organization

Harvard UniversityWuhan University People's Hospital

Active Organization

Harvard UniversityWuhan University People's Hospital

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

We report the development of the first positron emission tomography (PET) radiotracer, [¹⁸F]CNY-07, based on a highly specific and potent RIPK1 inhibitor, Nec-1s, for RIPK1/necroptosis brain imaging in rodents. [¹⁸F]CNY-07 was synthesized through copper-mediated ¹⁸F-radiolabeling from an aryl boronic ester precursor and studied in vivo PET imaging in rodents. PET imaging results showed that [¹⁸F]CNY-07 can penetrate the blood-brain barrier with a maximum percent injected dose per unit volume of 3 at 10 min postinjection in the brain in vivo. Self-blocking studies of [¹⁸F]CNY-07 by pretreating with unlabeled molecules in rodents showed reduced radioactivity in animal brains (30% radioactivity decreased), indicating the binding specificity of our radiotracer. Our studies demonstrate that [¹⁸F]CNY-07 has provided a useful PET radioligand enabling brain RIPK1 imaging, which could be a valuable research tool in studying RIPK1-related neurological disorders in animals and potentially humans.

100 Deals associated with 18F-CNY-07

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Central Nervous System Diseases	Preclinical	United States	Harvard University	25 May 2023
Central Nervous System Diseases	Preclinical	China	Wuhan University People's Hospital	25 May 2023